Sponsor

The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name The Fourth Affiliated Hospital of Zhejiang University School of Medicine appears in 17 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials17
Recruiting shown6
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

17 shown
Evaluation System for Lecanemab Efficacy Using Gold Electrode ECL to Monitor Alzheimer's BiomarkersNCT07688460 · lead sponsor · 2026-07-10
RECRUITING
miR-342-5p/AnkG Pathway in Early AD Synaptic DysfunctionNCT07353502 · lead sponsor · 2025-06-20
RECRUITING
Research on Building and Application of Internet-based Home Pre-rehabilitation Model for Lung Surgery Patients.NCT06458894 · lead sponsor · 2024-08-24
RECRUITING
Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's DiseaseNCT06356662 · lead sponsor · 2024-01-23
RECRUITING
Analysis of the Microenvironment of Lung Cancer and Exploration of the Mechanism of Resistance to ImmunotherapyNCT05636605 · lead sponsor · 2018-01-01
RECRUITING
Biomarkers and Pharmacogenomics for Precision Depression TherapyNCT07738497 · lead sponsor · 2026-07-01
NOT_YET_RECRUITING
RWS of of Liraglutide Alone and in Combination With Orlistat for Weight Loss in Overweight/Obese Patients.NCT07301437 · lead sponsor · 2026-05-01
NOT_YET_RECRUITING
The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLDNCT07289750 · lead sponsor · 2026-05-01
NOT_YET_RECRUITING
Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver MetastasisNCT07545213 · lead sponsor · 2026-04-20
NOT_YET_RECRUITING
Research on the Needs, Feasibility, and Intervention Effects of AI Health Coach-based Just-in-Time Adaptive Intervention (JITAI) in Weight Management for Overweight/Obese AdultsNCT07682571 · lead sponsor · 2026-03-01
COMPLETED
IONM During Radical ProstatectomyNCT06950216 · lead sponsor · 2025-04-01
NOT_YET_RECRUITING
Artificial Intelligence in Detecting Cardiac FunctionNCT06444425 · lead sponsor · 2024-06-01
ENROLLING_BY_INVITATION
Combined Statin and PD-1/PD-L1 Inhibitors in Treating Non-small Cell Lung CancerNCT05636592 · lead sponsor · 2022-10-15
ACTIVE_NOT_RECRUITING
Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung CancerNCT05004974 · lead sponsor · 2022-04-26
UNKNOWN
Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC PatientsNCT04552613 · lead sponsor · 2020-11-23
COMPLETED
Steroid Diabetes in Patients With Kidney DiseaseNCT06161701 · collaborator · 2024-01-10
RECRUITING
Quality Control and Evaluation in Standard COPD ManagementNCT03314077 · collaborator · 2017-11-01
COMPLETED

Drugs studied in this sponsor's trials

4 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing The Fourth Affiliated Hospital of Zhejiang University School of Medicine as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
Actoplus Met1
lecanemab1
pemigatinib1
tenofovir disoproxil fumarate1

Sponsor roles

lead sponsor15
collaborator2
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.